The star of the acquisition is the enzyme replacement therapy INZ-701, being developed for the rare disease ENPP1 deficiency.

Over Lars Fruergaard Jørgensen's eight years as CEO, Novo’s sales, profits and share price have almost tripled, the company ...

Lilly will use Rznomics’ proprietary ribozyme technology to develop RNA editing therapies for congenital hearing loss.

The FDA also approved the use of Zynyz as a monotherapy for patients with squamous cell carcinoma of the anal canal who are ...

Since Elevidys' accelerated approval in 2023, experts have been clamoring for more data, particularly in older and ...

Roche committed $50 billion in U.S. manufacturing funds, with which it will construct at least four new facilities.

The commitment is part of Roche’s recently announced $50 billion investment in the U.S., but a company spokesperson said that ...

Sanofi expects to add “a significant number of high-paying jobs” in the U.S. with $20 billion investment through 2030.

As the FDA prepares for a busy Oncologic Drugs Advisory Committee meeting next week, an agency insider told BioSpace that ...

Currently trailing Eli Lilly and Structure Therapeutics in the oral weight loss space, Novo Nordisk strikes a deal with ...

The Most Favored Nation directive would allow drugmakers to directly sell their products to patients at a lower cost, cutting ...

AbbVie's Emrelis is the first non-small cell lung cancer therapy approved for patients with high c-Met expression levels who ...